Okyo Pharma Ltd. (OKYO)
NASDAQ (CM) NASDAQ (CM) Primary 
XMUN Summary
OKYO Pharma files annual report, highlights cash position and Phase 3 trial plans
OKYO Pharma Ltd (NASDAQ:OKYO) announced on Monday that it has filed its annual report on Form 20-F for the fiscal year ended March 31, 2026, with the US Securities and Exchange Commission, while outlining its financial position and progress toward a planned Phase 3 clinical trial for its lead drug candidate. The clinical-stage biopharmaceutical company said the annual report is available through the SEC and its investor relations website.
OKYO Pharma advances toward Phase 3 FDA trial - ICYMI
OKYO Pharma Ltd (NASDAQ:OKYO) earlier this week reported positive feedback from its Type D meeting with the US Food and Drug Administration (FDA), providing greater regulatory clarity as the company advances urcosimod toward a global Phase 3 pivotal study for neuropathic corneal pain (NCP). Chief executive Robert Dempsey said the FDA's feedback supports a streamlined development strategy that could allow the company to conduct a single-dose Phase 3 study with the potential to serve as a single pivotal trial.
FTSE 100 Live: Stocks called higher as Trump signals Iran ready for talks
FTSE 100 Live pre-open Blue-chip stocks in London and mainland Europe are set to rebound on Thursday after reports that the US and Iran could agree a new...
Okyo Pharma Ltd. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Matthew Okkerse Dauntless Investment Group LLC | 3,819 | $9,814.83 | $5,556.64 | -$4,258.19 | -43.39% |
Okyo Pharma Ltd. (OKYO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Okyo Pharma Ltd. ever had a stock split?
Okyo Pharma Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Robert J. Dempsey CEO | NASDAQ (CM) Exchange | 679345108 CUSIP |
| GB Country | 4 Employees | - Last Dividend | - Last Split | 17 May 2022 IPO Date |
Overview
OKYO Pharma Limited is a clinical-stage biopharmaceutical company based in the United Kingdom, dedicated to the development of innovative therapeutics for patients afflicted with inflammatory eye diseases and ocular pain. The company, founded in 2007 and headquartered in London, has taken significant strides in the biopharmaceutical field, particularly focusing on conditions that affect eye health. With a strong commitment to addressing unmet medical needs, OKYO Pharma is at the forefront of researching and developing advanced treatments that promise to alleviate suffering and improve the quality of life for patients facing eye-related afflictions.
Products and Services
- OK-101
This lead preclinical product candidate is currently in Phase II clinical trials and represents OKYO Pharma’s pioneering approach to treating dry eye disease. Dry eye disease is a prevalent condition that can significantly impact an individual's quality of life, causing discomfort, and in severe cases, impairing vision. OK-101 is being developed with the aim of providing a novel, effective treatment option for patients who suffer from this condition, potentially improving their symptoms and overall eye health.
- OK-201
Another innovative venture by OKYO Pharma, OK-201 is a preclinical analogue candidate derived from bovine adrenal medulla. This lipidated-peptide is being developed for the treatment of neuropathic chronic pain, a condition that remains challenging to manage with current treatment options. By focusing on novel pathways and mechanisms, OKYO Pharma aims to contribute an important solution to the field of pain management, particularly for patients whose quality of life is severely affected by chronic pain conditions.
